Search
Vitamin E
go.drugbank.com/drugs/DB00163ApprovedInvestigationalNutraceuticalVet approvedIn 1922, vitamin E was demonstrated to be an essential nutrient[A32448]. … Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage[A176104].
International brands: Aquasol E, Amino-Opti-EMixtures: Collag-EN, Nutrol E-400 Plus Zinc Et Selenium CapEnsulizole
go.drugbank.com/drugs/DB11115ApprovedIt is commonly found in cosmetic products and sunscreen formulas in combination with other UV filter compounds due to its minimal protection against UV-A wavelengths. … Due to its water solubility, ensulizole is commonly used in products formulated to feel light and less oily [A32259].
Mixtures: Future E SPF 15, Lovely Me EX 32900042Products: Covergirl Outlast All Day Stay Fabulous 3-IN-1 FoundationDopamine
go.drugbank.com/drugs/DB00988ApprovedInvestigationalDopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action. … One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine.
Mixtures: INYECCION DE CLORHIDRATO DE DOPAMINA EN DEXTROSA AL 5% USP (1600 MCG/ML), Dopamine Hydrochloride in DextroseCategories: Compounds used in a research, industrial, or household settingBenzocaine
go.drugbank.com/drugs/DB01086ApprovedInvestigational[A231219] It is commonly used for local anesthesia in many over the counter products.[L32454,L32459,L32464] Benzocaine was first used for local anesthesia in dentistry.[A231259] … Benzocaine is an ester local anesthetic that acts by preventing transmission of impulses along nerve fibers and at nerve endings.
Mixtures: E-Vac Plus, Sanatos Lozenges EXProducts: Ez Access, Men Delay WipeQuetiapine
go.drugbank.com/drugs/DB01224ApprovedInvestigationalInitially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder.
Products: QUETIAPINA EG, QUETIAPINA EG STADABeclomethasone dipropionate
go.drugbank.com/drugs/DB00394ApprovedInvestigationalBeclomethasone dipropionate became first available in a pressurized metered-dose inhaler in 1972 and later in a dry powder inhaler and an aqueous nasal spray. … [L6871] It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP)[A179839] which acts on the glucocorticoid receptor to mediates its therapeutic action.
Mixtures: FORMODUAL N. 200/6UG, FORMODUAL N. 200/6UGProducts: GENTAMICINA E BECLOMETASONE DOC, VENTOLAIR MITE50UG 200H EAThreonine
go.drugbank.com/drugs/DB00156ApprovedInvestigationalNutraceuticalAn essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.
Mixtures: POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1000 ML, POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1500 MLDesipramine
go.drugbank.com/drugs/DB01151ApprovedThey contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. … The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission.
Synonyms: N-(3-methylaminopropyl)iminobibenzylGedatolisib
go.drugbank.com/drugs/DB11896ApprovedInvestigationalbreast cancer without a PIK3CA mutation detected, following progression on or after at least one line of endocrine therapy in the metastatic setting. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).
Amivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigationalFDA approved the subcutaneous formulation, RYBREVANT FASPRO™, across all existing and expanded indications of amivantamab, including its use as a first-line, chemotherapy-free combination regimen with … [A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022.